Advertisement

2016 San Antonio Breast Cancer Symposium

Breast Cancer

New Data on Prognostic Factors, Disease Detection, Drug Toxicities, and Treatment Adherence Presented at SABCS

The San Antonio Breast Cancer Symposium (SABCS) offers state-of-the-art information on all aspects of breast cancer biology, diagnosis, and treatment, drawing an international audience of more than 7,...

Breast Cancer

Expert Point of View: Amber Orman, MD

Amber Orman, MD, of the Department of Radiation Oncology, Breast Section, at Moffitt Cancer Center in Tampa, Florida, who was not involved in this study, said: “This study provides guidance when deci...

Breast Cancer

Autologous Breast Reconstruction Associated With Fewer Complications and Failures Than Implants in Women Who Have Received Radiation

Postmastectomy radiation is becoming more commonly used to treat breast cancer, and at the same time, there is an increasing trend among women to have breast reconstruction. Until now, oncologists hav...

Breast Cancer

Expert Point of View: Virginia Kaklamani, MD, and Melinda L. Telli, MD

Moderator of the press conference on this study, Virginia Kaklamani, MD, of the University of Texas Health Science Center at San Antonio, agreed that an improvement in response is important. “If you ...

Breast Cancer

Veliparib Improves Reponse but Not Progression-Free Survival in BRCA-Mutation Carriers

A randomized phase II study in women with metastatic breast cancer who have mutations in BRCA1 or BRCA2 evaluated the addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to combin...

Breast Cancer
Symptom Management

Randomized Trial Demonstrates Benefit of Scalp-Cooling in Prevention of Chemotherapy-Induced Hair Loss

A scalp-cooling device was found safe and effective in preventing chemotherapy-induced hair loss in women undergoing adjuvant treatment for breast cancer in an interim analysis of the first prospectiv...

Breast Cancer

Expert Point of View: Melinda L. Telli, MD

Melinda L. Telli, MD, Assistant Professor of Medicine at Stanford University Medical Center, Palo Alto, commented on this topic for The ASCO Post. She said the results of the two studies reinforce wh...

Breast Cancer

Tumor-Infiltrating Lymphocytes Prognostic in the Metastatic and Neoadjuvant Breast Cancer Settings

Studies presented at the 2016 San Antonio Breast Cancer Symposium added to growing evidence that tumor-infiltrating lymphocytes are important prognostic factors in breast cancer. One investigation eva...

Breast Cancer

Expert Point of View: Sara Hurvitz, MD; Mothaffar Rimawi, MD; and Carlos L. Arteaga, MD

Sara Hurvitz, MD, Director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, commented that in the United States, a bone mineral densit...

Breast Cancer

Ibandronate Fails to Improve Disease-Free Survival in Early Breast Cancer Patients—but With Favorable Trends

Addition of the oral bisphosphonate ibandronate to endocrine therapy did not significantly improve disease-free survival in patients with early breast cancer, according to the first results from the D...

Breast Cancer

Breast Cancer Experts Question New Recommendations for 21-Gene Recurrence Score Assay

At the 2016 San Antonio Breast Cancer Symposium, a group of breast cancer experts made a case for using the 21-gene Oncotype DX Breast Recurrence Score Assay in node-positive patients, despite ASCO’s ...

Breast Cancer

Selected Abstracts From the 2016 San Antonio Breast Cancer Symposium

Each year, The ASCO Post asks Jame Abraham, MD, Director of the Breast Oncology Program at Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program, to giv...

Breast Cancer

Expert Point of View: Steven Vogl, MD

Presentation of the PERTAIN study data by lead author Grazia Arpino, MD, PhD, was met with high interest at the 2016 San Antonio Breast Cancer Symposium. Steven Vogl, MD, of the Bronx, New York, comm...

Breast Cancer

Pertuzumab, Trastuzumab, Plus Aromatase Inhibitor Beneficial in Metastatic Breast Cancer

In the phase II PERTAIN study of locally advanced or metastatic hormone receptor–positive, HER2-positive breast cancer patients, the addition of pertuzumab (Perjeta) to a regimen of trastuzumab (Herc...

Breast Cancer

Expert Point of View: Howard A. “Skip” Burris, MD

Howard A. “Skip” Burris, MD, President of Clinical Operations and Chief Medical Officer at Sarah Cannon Research Institute, Nashville, commented on the poster presentation for The ASCO Post. He said ...

Breast Cancer

Novel Antibody-Drug Conjugate Targets Triple-Negative Breast Cancer

The antibody-drug conjugate sacituzumab govitecan (IMMU-132) produced high objective response rates, many of them quite durable, in a multicenter study of heavily pretreated patients with metastatic t...

Breast Cancer

Expert Point of View: Carlos L. Arteaga, MD

Press conference moderator ­Carlos L. Arteaga, MD, of Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, said that buparlisib will probably not be clinically useful, partly because it crosses the...

Breast Cancer

Buparlisib Phase III Findings: Glass Half Empty or Half Full?

The pan-phosphoinositide 3-kinase (PI3K) inhibitor buparlisib combined with fulvestrant (Faslodex) prolonged progression-free survival compared with placebo and fulvestrant in postmenopausal women wit...

Breast Cancer

Expert Point of View: Myles Brown, MD, Carlos L. Arteaga, MD, and Eric Winer, MD

Myles Brown, MD, Director of the Center for Functional Cancer Epigenetics at Dana-Farber Cancer Institute, Boston, suggested the failure of the endocrine therapy to increase the pathologic complete r...

Breast Cancer

Pathologic Complete Response Not Boosted by Addition of Estrogen Deprivation to Chemotherapy and Dual HER2 Blockade

The addition of estrogen deprivation to neoadjuvant chemotherapy and HER2 blockade did not enhance the achievement of pathologic complete responses in women with early-stage breast cancer, according ...

Breast Cancer

Expert Point of View: Carlos L. Arteaga, MD

Press conference moderator ­Carlos L. Arteaga, MD, said: “This drug is not necessarily the same as palbociclib [Ibrance] or ribociclib. There are subtle differences among these three [cyclin-dependent...

Breast Cancer

Abemaciclib Plus Anastrozole: Promising Signals Reported in Phase II Study of Early Breast Cancer

As neoadjuvant therapy, abemaciclib alone or in combination with anastrozole achieved strong signals of anticancer activity in postmenopausal patients with hormone receptor–positive, HER2-negative bre...

Breast Cancer
Genomics/Genetics

Expert Point of View: Leif Ellisen, MD, PhD

Results of this trial have been anticipated for a long time. Women were enrolled between 2000 and 2008,” said Leif Ellisen, MD, PhD, Program Director of Breast Medical Oncology at Massachusetts Gener...

Breast Cancer
Genomics/Genetics

BRCA Status Does Not Seem to Affect Survival Outcomes in Young Women With Early Breast Cancer

Young women who carry the BRCA1 and/or BRCA2 mutation and develop breast cancer seem to have similar survival compared with young women who have BRCA-negative breast cancer. However, women with BRCA-p...

Breast Cancer
Genomics/Genetics

Genomic Landscape of Metastatic Breast Cancer Differs From That of Primary Breast Cancer

Researchers working on whole-exome and transciptome sequencing of endocrine-resistant estrogen receptor–positive metastatic breast cancer have shown that the mutational landscape differs from that of ...

Breast Cancer

Expert Point of View: Virginia Kaklamani, MD

How can the results of this trial be applied to clinical practice? Press conference moderator, Virginia Kaklamani, MD, of the University of Texas Health Science Center in San Antonio, said: “The land...

Breast Cancer

Fulvestrant Plus Everolimus: New Second-Line Option for Postmenopausal Metastatic Breast Cancer

The addition of everolimus (Afinitor) to fulvestrant (Faslodex) doubled progression-free survival in postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer resista...

Breast Cancer

Expert Point of View: Michael Gnant, MD

Michael Gnant, MD, Professor of Surgery at the Medical University of Vienna in Austria and President of the Austrian Breast & Colorectal Cancer Study Group, was the invited discussant of the thre...

Breast Cancer

Benefit of Extended Adjuvant Endocrine Therapy Not Upheld in Multiple Studies Reported in San Antonio

Extended endocrine therapy with an aromatase inhibitor did not improve disease-free survival in patients with hormone receptor–positive breast cancer enrolled in three studies presented at the 2016 Sa...

breast cancer

Aleix Prat, MD, PhD, on HER2-Positive Breast Cancer: First Results of the PAMELA Trial (Spanish Language Version)

Aleix Prat, MD, PhD, of the University of Barcelona, discusses in Spanish study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual HER2 blockade wi...

breast cancer

Virginia G. Kaklamani, MD, DSc, on Early Breast Cancer: Year in Review

Virginia G. Kaklamani, MD, DSc, of The University of Texas Health Science Center, discusses new directions in prevention, early detection, and treatment of early-stage breast cancer, using genomic tes...

breast cancer

Monica Morrow, MD: Brinker Award Lecture Summary on Changing Paradigms in Local Therapy of Breast Cancer

Monica Morrow, MD, of Memorial Sloan Kettering Cancer Center, recognized at this year’s meeting for scientific distinction in clinical research, summarizes her Brinker Award lecture on modifying local...

breast cancer

S.P. Somashekhar, MBBS, MCh(Onco), on Watson for Oncology: A Validation Study for Breast Cancer

S.P. Somashekhar, MBBS, MCh(Onco), of the Manipal Comprehensive Cancer Centre, discusses a study to assess the performance of IBM's artificial intelligence platform in comparison to a multidisciplinar...

breast cancer

Eric P. Winer, MD: The McGuire Lecture

Eric P. Winer, MD, of the Dana-Farber Cancer Institute, summarizes his McGuire lecture on the past and future of breast cancer treatment.

breast cancer

Mothaffar Rimawi, MD, on HR-Positive, HER2-Positive Breast Cancer: Results of the NRG Oncology/NSABP B-52 Trial

Mothaffar Rimawi, MD, of the Smith Breast Center at Baylor College of Medicine, discusses phase II findings from a study evaluating pathologic complete response in patients with HR-positive, HER2-posi...

breast cancer
symptom management

Patricia A. Ganz, MD: Aromatase Inhibitors Data Review

Patricia A. Ganz, MD, of the UCLA Jonsson Comprehensive Cancer Center, summarizes two studies on using duloxetine for aromatase inhibitor–associated musculoskeletal symptoms, and aromatase inhibitors’...

breast cancer

Matthew P. Goetz, MD, on Advanced Breast Cancer: Expert Perspectives

Matthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.

breast cancer

Ruth O'Regan, MD, on Locally Advanced and Metastatic Breast Cancer: Results of the BELLE-3 Trial

Ruth O'Regan, MD, of the University of Wisconsin, discusses study findings on buparlisib plus fulvestrant in postmenopausal women with HR-positive, HER2-positive, aromatase inhibitor–treated, locally ...

breast cancer

Lisa A. Carey, MD, and Maki Tanioka, MD, on HER2+ Breast Cancer: Results From the CALGB 40601 Alliance Trial

Lisa A. Carey, MD, and Maki Tanioka, MD, both of the University of North Carolina, discuss study findings on weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer...

breast cancer

Lisa A. Carey, MD, and Ingrid A. Mayer, MD, on Triple-Negative Breast Cancer: Treatment Challenges

Lisa A. Carey, MD, of the University of North Carolina, and Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discuss the current studies on neoadjuvant systemic treatment in the triple-neg...

breast cancer

Lisa A. Carey, MD, on SABCS Meeting Highlights: Expert Perspective

Lisa A. Carey, MD, of the University of North Carolina, discusses a session she moderated on key data presented at SABCS, and gives her expert views on putting the research data into clinical practice...

cost of care
global cancer care
breast cancer

Peter Bach, MD, on The Global Cost of Cancer Care

Peter Bach, MD, of Memorial Sloan Kettering Cancer Center, summarizes his plenary lecture on drug costs and their effect on the affordability of cancer care worldwide (Plenary Lecture 3).

breast cancer
genomics/genetics

Nikhil Wagle, MD, on Breast Cancer: Advances in Genomics

Nikhil Wagle, MD, Dana-Farber Cancer Institute, discusses the genomic sequencing of ER-positive metastatic breast cancer that has become resistant to therapies and the implications for the choice of n...

breast cancer

Joseph A. Sparano, MD, on Early-Stage Breast Cancer: Findings on the Tumor Microenvironment

Joseph A. Sparano, MD, of the Montefiore Medical Center, discusses the tumor microenvironment of metastasis score and its association with early distant recurrence in HR-positive, HER2-negative early-...

breast cancer

Hyo Sook Han, MD, on Metastatic Breast Cancer: Trial Results on Veliparib, Carboplatin, and Paclitaxel

Hyo Sook Han, MD, of Moffitt Cancer Center, discusses phase II study findings on the efficacy and tolerability of veliparib in combination with carboplatin and paclitaxel vs placebo in patients with B...

breast cancer
symptom management

Anne Hudson Blaes, MD, on Aromatase Inhibitors and Cardiovascular Disease

Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).

symptom management
breast cancer

Jame Abraham, MD, on Hair Loss: SCALP Trial Results

Jame Abraham, MD, of the Cleveland Clinic, discusses findings of the Scalp Cooling Alopecia Prevention trial for patients with early-stage breast cancer (Abstract S5-02).

breast cancer

Jame Abraham, MD, on ER-Positive Breast Cancer: Expert Perspective on Initial Results of NRG Oncology/NSABP B-42

Jame Abraham, MD, of the Cleveland Clinic, gives his perspective on study results of extended adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer who have ...

breast cancer

Ruth O’Regan, MD, and Ann H. Partridge, MD, on The NRG Oncology/NSABP B-42, IDEAL, and DATA Studies

Ruth O’Regan, MD, of the University of Wisconsin, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss study findings from a session Dr. O’Regan moderated on three major trials addre...

breast cancer

Samuel Smith, PhD, on Tamoxifen Adherence: Results of the IBIS-1 Study

Samuel Smith, PhD, of Queen Mary University of London, discusses study findings on menopausal symptoms as predictors of long‐term adherence in an International breast cancer intervention study (Abstra...

Advertisement

Advertisement



Advertisement

click me